Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Down to $24.47

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCTGet Rating) gapped down prior to trading on Thursday . The stock had previously closed at $24.47, but opened at $23.90. Arcturus Therapeutics shares last traded at $22.70, with a volume of 20,755 shares trading hands.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald lowered their price objective on Arcturus Therapeutics from $93.00 to $86.00 in a research report on Tuesday, March 1st. HC Wainwright decreased their target price on shares of Arcturus Therapeutics from $47.00 to $25.00 in a research note on Tuesday, March 1st. Wells Fargo & Company decreased their target price on shares of Arcturus Therapeutics from $107.00 to $105.00 and set an “overweight” rating for the company in a research note on Friday, March 25th. Citigroup lowered shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the company from $86.00 to $29.00 in a research note on Thursday. Finally, Raymond James upgraded shares of Arcturus Therapeutics from an “underperform” rating to a “market perform” rating in a research note on Monday, January 31st. Six research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Hold” and an average target price of $43.63.

The stock has a market capitalization of $560.73 million, a PE ratio of -2.75 and a beta of 2.74. The firm has a 50 day moving average price of $24.29 and a 200 day moving average price of $32.28.

Arcturus Therapeutics (NASDAQ:ARCTGet Rating) last posted its quarterly earnings data on Monday, February 28th. The biotechnology company reported ($1.47) EPS for the quarter, topping the consensus estimate of ($1.77) by $0.30. The firm had revenue of $5.79 million during the quarter, compared to analyst estimates of $12.90 million. Arcturus Therapeutics had a negative return on equity of 61.88% and a negative net margin of 1,647.99%. During the same period in the prior year, the business posted ($1.25) EPS. Analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -4.59 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Allspring Global Investments Holdings LLC bought a new position in Arcturus Therapeutics in the 4th quarter worth $32,000. KRS Capital Management LLC bought a new position in Arcturus Therapeutics in the 4th quarter worth $51,000. Daiwa Securities Group Inc. boosted its holdings in Arcturus Therapeutics by 4,487.0% in the 3rd quarter. Daiwa Securities Group Inc. now owns 2,110 shares of the biotechnology company’s stock worth $101,000 after buying an additional 2,064 shares during the period. Byrne Asset Management LLC boosted its holdings in Arcturus Therapeutics by 29.4% in the 1st quarter. Byrne Asset Management LLC now owns 4,000 shares of the biotechnology company’s stock worth $108,000 after buying an additional 910 shares during the period. Finally, Point72 Hong Kong Ltd bought a new position in Arcturus Therapeutics in the 3rd quarter worth $116,000. Hedge funds and other institutional investors own 76.86% of the company’s stock.

About Arcturus Therapeutics (NASDAQ:ARCT)

Arcturus Therapeutics Holdings Inc, an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU.

Further Reading

Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.